References
1. Syro L.V., Rotondo F., Ramirez A., Leva A.D., et al. Progress in the diagnosis and classification of pituitary adenomas. Front Endocrinol (Lausanne). 2015; 12 (6): 97.
2. Gadelha M., Kasuki L., Korbonits M. The genetic background of acromegaly. Pituitary. 2017; 20 (1): 10.
3. Rostomyan L., Potorac I., Beckers P., Daly A.F., et al. AIP mutations and gigantism. Ann Endocrinol (Paris). 2017; 78 (2): 123-30.
4. Varadhan L., Reulen R.C., Brown V., Clayton R.N. The role of cumulative growth hormone exposure in determing mortality and morbidity in acromegaly: a single centre study. Pituitary. 2016; 19 (3): 251-61.
5. Holdaway I.M., Bolland M.J., Gamble G.D. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol. 2008; 159: 89-95.
6. Lloyd R.V., Kovacs K., Young W.F., Farrell W., et al. Pituitary tumors: introduction. In: R.A. DeLlelis, R.V. Lloyd, P.U. Heitz, C. Eng C (eds). Pathology and Genetics of Tumours of Endocrine Organs. Lyon: IARC Press, 2004: 10-3.
7. Lopes M.B. Growth hormone-secreting adenomas: pathology and cell biology. Neurosurg Focus. 2010; 29 (4): E2.
8. Gomez-Hernandez K., Ezzat S., Asa S.L., Mete O. Clinical implications of accurate subtyping of pituitary adenomas: perspectives from the treating physician. Turk Patoloji Derg. 2015; 31 (1): 4-17.9. Nishioka H., Inoshita N. New WHO classification of pituitary adenomas (4th edition): assessment of pituitary transcription factors and the prognostic histological factors. Brain Tumor Pathol. 2018; 35 (2): 57-61.
10. Asa S.L., Kucharczyk W., Ezzat S. Pituitary acromegaly: not one disease. Endocr Relat Cancer. 2017; 24 (3): 1-4.
11. Diamond L., O’Brien T.G., Baird W.M. Tumor promoters and the mechanism of tumor promotion. Adv Cancer Res. 1980; 32: 1-74.
12. Ferone D., Herder W.W., Pivonello R., et al. Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy. J Clin Endocr Metab. 2008; 93: 1412-17.
13. Pisarek H.M., Pawlikowski J., Kunert-Radek J., Radek M. Expression of somatostatin receptor subtypes in human pituitary adenomas - immunohistochemical studies. Endocrinol Pol. 2009; 60 (4): 240-51.
14. Sarkar S., Chacko A.G., Chacko G. An analysis of granulation patterns, MIB-1 proliferation indices and p53 expression in 101 patients with acromegaly. Acta Neurochir (Wien). 2014; 156 (12): 2221-30.
15. Melmed S. Acromegaly pathogenesis and treatment. J Clin Invest. 2009; 119: 3189-202.
16. Neto L.V., Machado O., Luque R.M., et al. Expression analysis of dopamine receptor subtypes in normal human pituitaries, nonfunctioning pituitary adenomas and somatotropinomas, and the association between dopamine and somatostatin receptors with clinical response to octreotide-LAR in acromegaly. J Clin Endocrinol Metab. 2009; 99: 2789-93.
17. Paraglioma R.M., Corsello S.M., Salvatori R. Somatostatin receptor ligands in acromegaly: clinical response and factors predicting resistance. Pituitary. 2017; 20 (1): 109-15.
18. Efstathiadou Z.A., Bargiota A., Chrisoulidou A., Kanakis G. Impact of gsp mutation in somatotroph pituitary adenomas on growth hormone response to somatostatin analogs: a meta-analysis. Pituitary. 2015; 18 (6): 861-7
19. Bhayana S., Booth G.L., Asa S.L., et al. The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly. J Clin Endocrinol Metab. 2005; 90: 6290-5.
20. Ezzat S., Asa S.L., Couldwell W.T., et al. The prevalence of pituitary adenomas: a systematic review. Cancer. 2004; 101: 613-9.
21. Ramos-Levi A.M., Bernabeu I., Sampedro-Nunez M., Marazuela M. Genetic predictors of response to different medical therapies in acromegaly. Prog Mol Biol Transl Sci. 2016; 138: 85-113.
22. Cuevas-Ramos D., Carmichael J.D., Cooper O., et al. A structural and functional acromegaly classification. J Clin Endocrinol Metab. 2015; 100 (1): 122-31.
23. Butz L.B., Sullivan S.E., Chandler W.F., Barcan A.L. "Micromegaly": an update on the prevalence of acromegaly with apparently normal GH secretion in the modern era. Pituitary. 2016; 19 (6): 547-51.
24. Gadelha M.R., Wildemberg L.E., Bronstein M.L., Gatto F., et al. Somatostatin receptor ligands in the treatment of acromegaly. Pituitary. 2017; 20 (1): 100-8.
25. Melmed S., Bronstein M.D., Chanson P., et al. A Consensus Statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol. 2018; 14 (9): 552-61.
26. Kasuki L., Wildemberg L.E., Gadelha M.R. Management of endocrine disease: Personalized medicine in the treatment of acromegaly. Eur J Endocrinol. 2018; 178 (3): 89-100.
27. Freda P.U., Katznelson L., van der Lely A.J., et al. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab. 2005; 90: 4465-73.
28. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001; 69: 89-95.
29. Gadelha M.R., Kasuki L., Korbonits M. Novel pathway for somatostatin analogs in patients with acromegaly. Trends Endocrinol Metab2013; 24: 238-46.
30. Babu H., Ortega A., Nuno M., Dehghan A., et al. Long-term endocrine outcomes following endoscopic endonasal transsphenoidal surgery for acromegaly and associated prognostic factors. Neurosurgery. 2017; 81: 357-66.
31. Sarkar S., Jacob K.S., Pratheesh R., Chacko A.G. Transsphenoidal surgery for acromegaly: predicting remission with early postoperative growth hormone assays. Acta Neurochir. 2014; 156: 1379-87.
32. Domingo M.P. Treatment of acromegaly in the era of personalised and predictive medicine. Clin Endocrinol (Oxf). 2015; 83 (1): 3-14.
33. Lamberts S.W., Uitterlinden P., Schuijff P.C., et al. Therapy of acromegaly with sandostatin: the predictive value of an acute test, the value of serum somatomedin-C measurements in dose adjustment and the definition of a biochemical "cure". Clin Endocrinol. 1988; 29: 411-20.
34. Taboada G.F., Luque R.M., Neto L.V., et al. Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR. Eur J Endocrinol. 2008; 158: 295-303.
35. Plockinger U., Albrecht S., Mawrin C., et al. Selective loss of somatostatin receptor 2 in octreotide-resistant growth hormone-secreting adenomas. J Clin Endocrinol Metab. 2008; 93: 1203-10.
36. Casar-Borota O., Heck A., Schulz S., et al. Expression of SSTR2a, but not of SSTRs 1, 3, or 5 in somatotroph adenomas assessed by monoclonal antibodies was reduced by octreotide and correlated with the acute and long-term effects of octreotide. J Clin Endocrinol Metab. 2013; 98: 1730-39.
37. Halah F.P., Elias L.L., Martinelli C.E., Castro M., et al. Usefulness of subcutaneous or long-acting octreotide as a predictive test and in the treatment of acromegaly. Arg Bras Endocrinol Metabol. 2004; 48 (2): 245-52.
38. Biermasz N.R., Pereira A.M., Smit J.W., et al. Intravenous octreotide test predicts the long term outcome of treatment with octreotide-long-acting repeatable in active acromegaly. Growth Hormone IGF Res. 2005; 15: 200-6.
39. Gilbert J.A., Miell J.P., Chambers S.M., Aulwin S.J. The nadir growth hormone after an octreotide test dose predicts the long-term efficacy of somatostatin analogue therapy in acromegaly. Clin Endocrinol (Oxf). 2005; 62 (6): 742-7.
40. Halperin I., Nicolau J., Casamitjana R., et al. A short acute octreotide test for response prediction of long-term treatment with somatostatin analogues in acromegalic patients. Horm Metab Res. 2008; 40 (6): 422-6.
41. Bandgar T.R., Sarathi V., Shivane V., et al. The value of an acute octreotide suppression test in predicting response to long-term somatostatin analogue therapy in patients with acromegaly. J Postgrad Med. 2010; 56: 7-11.
42. Wang M., Shen M., He W., et al. The value of an acute octreotide suppression test in predicting short-term efficacy of somatostatin analogues in acromegaly. Endocr J. 2016; 63 (9): 819-34.
43. Colao A., Auriemma R.S., Lombardi G., et al. Resistance to somatostatin analogs in acromegaly. Endocr Rev. 2011; 32: 247-71.
44. Pronin V.S., Poteshkin Y.E., Gitel E.P., et al. The Present Strategy of Diagnostic and Treatment of sSomatotropinoms. Moscow: GEOTAR-Media, 2013: 191 p. (in Russian)
45. Heck A., Ringstad G., Fougner S.L., et al. Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly. Clin Endocr. 2012; 77: 72-8.
46. Shen M., Zhang Q., Liu W., et al. Predictive value of T2 relative signal intensivity for response to somatostatin analogs in newly diagnosed acromegaly. Neuroradiology. 2016; 58 (11): 1057-65.
47. Puig-Domingo M., Resmini E., Gomez-Anson B., et al. Magnetic resonance imaging as a predictor of response to somatostatin analogs in acromegaly after surgical failure. J Clin Endocrinol Metab. 2010; 95: 4973-78.
48. Kocak B., Durmaz E.S., Kadioglu P., Korkmaz P., et al. Predicting response to somatostatin analogues in acromegaly: machine learning-based high-dimensional quantitative texture analysis on T2-weighted MRI. Eur Radiol. 2019; 29 (6): 2731-39.
49. Luque R.M., Sanchez-Tejada L., Ibanez-Costa A., et al. OR26-1 REMAH: The Spanish Molecular Registry of Pituitary Adenomas. A Clinical-Molecular Multicenter Research Network to Study Pituitary Adenomas: Initial Data on the Molecular Profile of GH-producing Adenomas. ENDO. San Francisco, 2013.
50. Kiseljak K., Xu M., Mills T., Smith T.T., et al. Differential somatostatin receptor (SSTR) 1-5 expression and downstream effectors in histologic subtypes of growth hormone pituitary tumors. Mol Cell Endocrinol. 2015; 417: 73-83.
51. Gatto F., Diermasz N.R., Filders R.A., Kros J.M., et al. Low beta-arrestin expression correlates with the responsiveness to long-term somatostatin analog treatment in acromegaly. Eur J Endocrinol. 2016; 174 (5): 651.
52. Ballare E., Persani L., Lania A.G., et al. Mutation of somatostatin receptor type 5 in an acromegalic patient resistant to somatostatin analog treatment. J Clin Endocrinol Metab. 2001; 86: 3809-14.
53. Duran-Prado M., Saveanu A., Luque R.M., et al. A potential inhibitory role for the new truncated variant of somatostatin receptor 5, sst5TMD4, in pituitary adenomas poorly responsive to somatostatin analogs. J Clin Endocrinol Metab. 2010; 95: 2497-502.
54. Oberg K., Lamberts S.W. Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future. Endocr Relat Cancer. 2016, 23 (12): 551-66.
55. Howlett T.A., Willis D., Walker G., Wass J.A., et al.; and Group UKARS. Control of growth hormone and IGF1 in patients with acromegaly in the UK: responses to medical treatment with somatostatin analogues and dopamine agonists. Clin Endocrinol. 2013; 79: 689-99.
56. Chahal H.S., Trivellin G., Leontiou C.A., et al. Somatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway. J Clin Endocrinol Metab. 2012; 97: 1411-20.
57. Cannavo S., Ferrau F., Ragonese M., Curto L., et al. Increased prevalence of acromegaly in a highly polluted area. Eur J Endocrinol. 2010; 163 (4): 509-13.
58. Kasuki L., Vieira Neto L., Wildemberg L.E., Colli L.M., et al. AIP expression in sporadic somatotropinomas is a predictor of the response to octreotide LAR therapy independent of SSTR2 expression. Endocr Relat Cancer. 2012; 19: 25-9.
59. Chahal H.S., Trivellin G., Leontiou C.A., Alband N., et al. Somatostatin analogs modulate AIP in somatotroph adenomas - the role of the ZAC1 pathway. J Clin Endocrinol Metab. 2012; 97: 1411-20.
60. Maffezzoni F., Formenti A.M., Mazziotti G., Frara S., et al. Current and future medical treatment for patients with acromegaly. Expert Opin Pharmacother. 2016; 17 (12): 1631-42.